MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Significance: Ovarian cancer is the leading cause of death among gynecological malignancies and has a poor prognosis characterized by resistance to chemotherapy. MCL1 has been found to play an essential role in chemoresistance and could be a promising therapeutic target. However, designing specific inhibitors targeting MCL1 remains challenging. Here, we found that deubiquitinating enzyme 3 (DUB3) stabilizes MCL1 via deubiquitination. We identified that O 6-methylguanine-DNA methyltransferase (MGMT) is a key activator of DUB3 transcription and that the MGMT inhibitor PaTrin-2 effectively suppresses ovarian cancer cells with elevated MGMT-DUB3-MCL1 expression. We further showed that histone deacetylase (HDAC) inhibitors could significantly activate MGMT/DUB3 expression to sensitize ovarian cancer cells to PaTrin-2, providing an ideal therapeutic option involving the combined treatment of HDACis and PaTrin-2 in ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · cited 1×
“The B-cell lymphoma 2 (BCL-2) family encodes more than 20 proteins, including proapoptotic and antiapoptotic proteins that regulate the intrinsic apoptosis pathway, which maintains the balance between cell survival and cell death (3).”
BackgroundNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404 · cited 1×
“In our study, these three HDACis mainly targeted the class I HDACs (HDAC1, HDAC2, and HDAC3) (31), illustrating that different HDAC family members might activate DUB3 via various mechanisms.”
BackgroundThe MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Cited by
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
“Based on lines of pre-clinical Lomeguatrib (PaTrin-2) Direct repair MGMT Pancreatic cancer cells; combination with HDACis in ovarian cancer Wu et al. (2019), Shi et al. (2020) Lucanthone BER APE1 Glioblastoma multiforme (GBM) cell Chowdhury et al. (2015) CRT0044876 BER APE1 Colon cancer cell lines…”
MethodDewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Interplay between protein acetylation and ubiquitination controls MCL1 protein stability
Shimizu, K., Gi, M., Suzuki, S., North, B. J., Watahiki, A., Fukumoto, S., Asara, J. M., Tokunaga, F., Wei, W., & Inuzuka, H. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109988 · Cited by 62
“…and Parkin) (Carroll et al., 2014; Ding et al., 2007; Harley et al., 2010; Inuzuka et al., 2011; Magiera et al., 2013; Wertz et al., 2011; Zhong et al., 2005) and deubiquitinases (DUBs) (e.g., USP9X, USP13, DUB3, and JOSD1) (Schwickart et al., 2010; Wu et al., 2019, 2020; Zhang et al., 2018).”
Metadata
- Authors
- Wu, X., Luo, Q., Zhao, P., Chang, W., Wang, Y., Shu, T., Ding, F., Li, B., & Liu, Z.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-02-04
- Volume
- 116
- Issue
- 8
- Pages
- 2961-2966
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2912404095
- Cited by
- 89
- References
- 5
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. https://app.cochat.ai/papers/10.1073/pnas.1814742116
- The paper
- Wu, X., Luo, Q., Zhao, P., Chang, W., Wang, Y., Shu, T., Ding, F., Li, B., & Liu, Z. (2019). MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1814742116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.